- Home
- NVX vs ACIU Comparison
NVX vs ACIU Comparison
Compare NVX & ACIU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NVX | ACIU |
|---|---|---|
| Founded | 2012 | 2003 |
| Country | Australia | Switzerland |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 245.7M | 213.3M |
| IPO Year | N/A | 2016 |
Fundamental Metrics
Financial Performance| Metric | NVX | ACIU |
|---|---|---|
| Price | $1.01 | $2.92 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $10.00 |
| AVG Volume (30 Days) | 1.2M | ★ 1.4M |
| Earning Date | 01-28-2026 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $5,931,433.00 | $5,482,957.00 |
| Revenue This Year | $165.90 | N/A |
| Revenue Next Year | $1,344.85 | $738.95 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.81 | $1.43 |
| 52 Week High | $3.86 | $4.00 |
Technical Indicators
Market Signals| Indicator | NVX | ACIU |
|---|---|---|
| Relative Strength Index (RSI) | 37.27 | 47.51 |
| Support Level | $1.07 | $2.54 |
| Resistance Level | $1.05 | $3.45 |
| Average True Range (ATR) | 0.06 | 0.31 |
| MACD | 0.01 | 0.03 |
| Stochastic Oscillator | 9.52 | 30.95 |
Price Performance
Historical ComparisonAbout NVX NOVONIX Limited American Depository Shares
NOVONIX Ltd operates in the lithium-ion battery industry. The company has three operating segments namely Graphite Exploration, Battery Technology, and Battery Materials. Graphite Exploration segment is engaged in the exploration and development of high-grade flake graphite deposits. The Battery Technology segment develops battery cell testing equipment and carries out research and development in battery development. The Battery Materials segment develops and manufactures battery anode materials. The Battery Technology segment generates maximum revenue for the company.
About ACIU AC Immune SA
AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses mostly of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.